Free Trial
→ Trump To Relaunch USD? (From Porter & Company) (Ad)tc pixel
NASDAQ:BIAF

bioAffinity Technologies Q3 2025 Earnings Results & Report

bioAffinity Technologies logo
$3.52 -0.12 (-3.17%)
As of 02:55 PM Eastern
This is a fair market value price provided by Massive. Learn more.

bioAffinity Technologies met analyst earnings expectations and beat on revenue in its Q3 2025 results, released November 14, 2025. The company reported EPS of -$40.50 versus the -$40.50 consensus estimate, while revenue of $1.45 million topped the $1.41 million estimate by $0.04 million.

Research:ProfileEarnings HistoryForecast

Earnings Announcement Details

Quarter
Q3 2025
Report Date
Time
Before Market Opens
Conference Call
8:30 AM ET

bioAffinity Technologies EPS Results

Actual EPS
-$40.50
Consensus EPS
-$40.50
Beat/Miss
Met Expectations
One Year Ago EPS
N/A
EPS Beat Rate
3 of last 7 quarters

bioAffinity Technologies Revenue Results

Actual Revenue
$1.45 million
Expected Revenue
$1.41 million
Beat/Miss
Beat by +$35.07 thousand
YoY Revenue Growth
N/A

Upcoming Earnings

bioAffinity Technologies' Q3 2026 earnings is estimated for Wednesday, November 18, 2026, based on past reporting schedules

Conference Call Resources

Powered by Quartr

Earnings Documents

bioAffinity Technologies' Q3 2025 Earnings ReleaseEarnings Release
(8-K)
bioAffinity Technologies' Q3 2025 Quarterly ReportQuarterly Report
(10-Q)

bioAffinity Technologies Q3 2025 Earnings FAQ

bioAffinity Technologies (NASDAQ:BIAF) reported earnings of -$40.50 per share for Q3 2025, matching the consensus estimate of -$40.50. The report was announced on Friday, November 14, 2025.

bioAffinity Technologies reported revenue of $1.45 million for Q3 2025, against a consensus estimate of $1.41 million.

bioAffinity Technologies' next earnings date is estimated for Wednesday, November 18, 2026. MarketBeat tracks confirmed and estimated earnings dates for bioAffinity Technologies on the company's earnings history page.

bioAffinity Technologies Earnings Headlines

bioAffinity to Present New Sputum-Based Lung Biomarker Data
October 13 at 9:51 AM  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/bioaffinity-to-present-new-sputum-based-lung-biomarker-data?utm_source=marketbeat.com&utm_medium=referral
BioAffinity Technologies Closes $4 Million Direct Offering, Private Placement
October 9, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/markets/stocks/articles/bioaffinity-technologies-closes-4-million-161341113.html
Trump's about to unleash his Midterm Weapon
Trump is turning the midterms into a referendum on American energy, pushing for more oil, more gas, and lower prices before November 3. One small oil and gas company sits atop the largest oil and gas deposit ever found on American soil and is integrating AI technology into its wells, with margins rivaling firms valued ten times higher. A previous stock pick from this same screening process rose more than 1,000 percent in under 12 months.tc pixel
October 14 at 1:00 AM  |  Monument Traders Alliance (Ad)
bioAffinity Technologies Completes New $4 Million Financing
October 9, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/bioaffinity-technologies-completes-new-4-million-financing?utm_source=marketbeat.com&utm_medium=referral
WallachBeth Capital Announces Closing of bioAffinity Technologies $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
October 9, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/wallachbeth-capital-announces-closing-of-bioaffinity-technologies-4-million-registered-direct-financing-of-common-stock-and-concurrent-private-placement-priced-at-the-market-under-nasdaq-rules-302903691.html
bioAffinity Technologies, Inc. Announces Closing of $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules
October 9, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20261009218447/en/bioaffinity-technologies-inc.-announces-closing-of-4-million-registered-direct-financing-of-common-stock-and-concurrent-private-placement-priced-at-the-market-under-nasdaq-rules/
See More bioAffinity Technologies Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like bioAffinity Technologies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on bioAffinity Technologies and other key companies, straight to your email.

About bioAffinity Technologies

bioAffinity Technologies (NASDAQ:BIAF) is a biotechnology company focused on developing diagnostic and therapeutic products for cancer and other diseases. The company’s technology platform uses porphyrin-based compounds designed to selectively interact with cancer cells, supporting applications in disease detection and treatment.

Its lead diagnostic product, CyPath Lung, is a noninvasive urine-based test being developed to aid in the detection of lung cancer. The test is designed to use a porphyrin-based agent that interacts with abnormal cells in the lungs and can subsequently be detected in a urine sample. CyPath Lung has received Breakthrough Device designation from the U.S. Food and Drug Administration, although regulatory status and availability may vary by jurisdiction.

bioAffinity Technologies is headquartered in Albuquerque, New Mexico, and serves the medical and biotechnology markets through the development of products intended to improve the early identification and treatment of cancer. The company is led by Maria Zannes, who serves as president and chief executive officer.

View bioAffinity Technologies Profile
Earnings Tools